[{"id":"d02f7b2d-1c37-4780-a6b7-7db1aff0b46d","acronym":"PBCAR0191-01","url":"https://clinicaltrials.gov/study/NCT03666000","created_at":"2021-01-18T17:59:15.398Z","updated_at":"2025-02-25T15:10:55.408Z","phase":"Phase 1","brief_title":"Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL","source_id_and_acronym":"NCT03666000 - PBCAR0191-01","lead_sponsor":"Imugene Limited","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV • azercabtagene zapreleucel (PBCAR0191) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 129","initiation":"Initiation: 03/11/2019","start_date":" 03/11/2019","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-13"},{"id":"e97d1c38-f15b-4c9e-80f3-19d6d48099bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04649112","created_at":"2021-01-19T20:40:23.197Z","updated_at":"2024-07-02T16:36:00.679Z","phase":"Phase 1","brief_title":"Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies","source_id_and_acronym":"NCT04649112","lead_sponsor":"Precision BioSciences, Inc.","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azercabtagene zapreleucel (PBCAR0191) • PBCAR19B"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 06/16/2021","start_date":" 06/16/2021","primary_txt":" Primary completion: 12/22/2022","primary_completion_date":" 12/22/2022","study_txt":" Completion: 09/30/2023","study_completion_date":" 09/30/2023","last_update_posted":"2022-11-09"}]